A subscription to JoVE is required to view this content. Sign in or start your free trial.
Detailed protocols for both in vitro and in-cell selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) experiments to determine the secondary structure of pre-mRNA sequences of interest in the presence of an RNA-targeting small molecule are presented in this article.
In the process of drug development of RNA-targeting small molecules, elucidating the structural changes upon their interactions with target RNA sequences is desired. We herein provide a detailed in vitro and in-cell selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) protocol to study the RNA structural change in the presence of an experimental drug for spinal muscular atrophy (SMA), survival of motor neuron (SMN)-C2, and in exon 7 of the pre-mRNA of the SMN2 gene. In in vitro SHAPE, an RNA sequence of 140 nucleotides containing SMN2 exon 7 is transcribed by T7 RNA polymerase, folded in the presence of SMN-C2, and subsequently modified by a mild 2'-OH acylation reagent, 2-methylnicotinic acid imidazolide (NAI). This 2'-OH-NAI adduct is further probed by a 32P-labeled primer extension and resolved by polyacrylamide gel electrophoresis (PAGE). Conversely, 2'-OH acylation in in-cell SHAPE takes place in situ with SMN-C2 bound cellular RNA in living cells. The pre-mRNA sequence of exon 7 in the SMN2 gene, along with SHAPE-induced mutations in the primer extension, was then amplified by PCR and subject to next-generation sequencing. Comparing the two methodologies, in vitro SHAPE is a more cost-effective method and does not require computational power to visualize results. However, the in vitro SHAPE-derived RNA model sometimes deviates from the secondary structure in a cellular context, likely due to the loss of all interactions with RNA-binding proteins. In-cell SHAPE does not need a radioactive material workplace and yields a more accurate RNA secondary structure in the cellular context. Furthermore, in-cell SHAPE is usually applicable for a larger range of RNA sequences (~1,000 nucleotides) by utilizing next-generation sequencing, compared to in vitro SHAPE (~200 nucleotides) that usually relies on PAGE analysis. In case of exon 7 in SMN2 pre-mRNA, the in vitro and in-cell SHAPE derived RNA models are similar to each other.
Selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE) is a method of measuring the kinetics of each nucleotide in an RNA sequence of interest and elucidating the secondary structure at single-nucleotide resolution1. SHAPE methodologies, both in in vitro conditions2,3,4 (purified RNA in a defined buffer system) and in living mammalian cells5,6, have been developed to investigate the secondary structure of medium length RNA sequences (typically <1,000 nucleotides for in-cell SHAPE and <200 nucleotides for in vitro SHAPE). It is particularly useful to evaluate structural changes in receptor RNA upon binding to RNA-interacting small molecule metabolites2,4,7,8 and to study mechanistic actions of RNA-targeting molecules during drug development9,10.
RNA-targeting drug discovery has recently drawn attention in academic laboratories and the pharmaceutical industry11,12 via different approaches and strategies13,14,15,16. Recent examples of RNA-targeting small molecules for clinical use include two structurally distinct experimental drugs, LMI-07017 and RG-791618,19, for spinal muscular atrophy (SMA), which showed promising results in phase II clinical trials20. Both molecules were demonstrated to target survival of motor neuron (SMN) 2 pre-mRNA and regulate the splicing process of the SMN2 gene6,17,21. We previously demonstrated the application of in vitro and in-cell SHAPE in an examination of the target RNA structural changes in the presence of an analog of RG-7916 known as SMN-C26.
In principle, SHAPE measures the 2'-OH acylation rate of each nucleotide of an RNA sequence in the presence of excess amounts of a self-quenching acylation reagent in an unbiased manner. The acylation reagent is not stable in water, with a short half-life of (e.g., T1/2 = 17 s for 1-methyl-7-nitroisatoic anhydride; or 1M7, ~20 min for 2-methylnicotinic acid imidazolide, or NAI)22 and insensitivity to the identity of the bases23. This results in a more favorable acylation of the 2'-OH groups of flexible bases, which can be transformed into an accurate assessment of the dynamics of each nucleotide. Specifically, a nucleotide in a base-pair is usually less reactive than an unpaired one to a 2'-OH modifying reagent, such as NAI and 1M7.
Looking at the source of the RNA template and where 2'-OH acylation takes place, SHAPE can generally be categorized into in vitro and in-cell SHAPE. In vitro SHAPE uses purified T7 transcribed RNA and lacks a cellular context in experimental designs. In in-cell SHAPE, both the RNA template transcription and 2'-OH acylation occur within living cells; therefore, the results can recapitulate the RNA structural model in a cellular context. In-cell SHAPE has been referred to as in vivo SHAPE for the SHAPE carried in living cells in the literature24. Since this experiment is not performed in an animal, we termed this experiment as in-cell SHAPE for accuracy.
The strategies for the primer extension stage of in vitro and in-cell SHAPE are also different. In in vitro SHAPE, reverse transcription stops at the 2'-OH acylation position in the presence of Mg2+. A 32P-labled primer extension therefore appears as a band in polyacrylamide gel electrophoresis (PAGE) and the intensity of the band is proportional to the acylation rate1. In in-cell SHAPE, reverse transcription generates random mutations at the 2'-OH adduct position in the presence of Mn2+. The mutational rate of each nucleotide can be captured by in depth next-generation sequencing, and the SHAPE reactivity at single-nucleotide resolution can then be calculated.
A potential problem for in-cell SHAPE is the low signal-to-noise ratio (i.e., a majority of the 2'-OH groups is unmodified, while the unmodified sequences occupy most of the read in next-generation sequencing). Recently, a method to enrich the 2'-OH modified RNA, referred to as in vivo click SHAPE (icSHAPE), was developed by the Chang laboratory25. This enrichment method may be advantageous in studying weak small molecules such as RNA interactions, especially in a transcriptome-wide interrogation.
1. In Vitro SHAPE
NOTE: The protocol is modified from the published protocol1.
2. In-cell SHAPE
We previously demonstrated that an RNA splicing modulator, SMN-C2, interacts with AGGAAG motif on exon 7 of the SMN2 gene's pre-mRNA, and used SHAPE to assess the RNA structural changes in the presence of SMN-C26. The binding site of SMN-C2 is distinct from the FDA-approved antisense oligonucleotide (ASO) for SMA, nusinersen, which binds and blocks the intronic splicing silencer (ISS) on intron 727,28 (...
In in vitro SHAPE, it is critical to use high quality homogeneous RNA template. T7 transcription, however, often yields heterogeneous sequences36. Especially, sequences with ±1 nucleotide at the 3'-terminus with non-negligible yields36 are usually difficult to be removed by polyacrylamide gel purification. Heterogeneous RNA template can result in more than one set of the signal in the sequencing gel profiling of the primer extension product, which sometimes makes i...
The authors declare no conflict of interest.
This work was made possible by the NIH R01 grant (NS094721, K.A.J.).
Name | Company | Catalog Number | Comments |
DNA oligonucleotide | IDT | gBlock for > 200 bp DNA synthesis | |
Phusion Green Hot Start II High-Fidelity PCR Master Mix | Thermo Fisher | F566S | |
NucleoSpin gel and PCR clean-up kit | Takara | 740609.50 | |
MegaScript T7 transcription kit | Thermo Fisher | AM1333 | Contains 10X reaction buffer, T7 enzyme, NTP and Turbo DNase |
DEPC-treated water | Thermo Fisher | 750023 | |
2X TBE-urea sample buffer | Thermo Fisher | LC6876 | |
40% acrylamide/ bisacrylamide solution (29:1) | Bio-Rad | 1610146 | |
10X TBE buffer | Thermo Fisher | 15581044 | |
Nalgene Rapid-Flow™ Filter Unit | Thermo Fisher | 166-0045 | |
Kimwipe | Kimberly-Clark | 34133 | |
TEMED | Thermo Fisher | 17919 | |
SYBR-Safe dye | Thermo Fisher | S33102 | |
6 % TBE-urea mini-gel | Thermo Fisher | EC6865BOX | |
ChemiDoc | Bio-Rad | ||
T4 PNK | NEB | M0201S | |
γ-32P-ATP | Perkin Elmer | NEG035C005MC | |
Hyperscreen™ Intensifying Screen | GE Healthcare | RPN1669 | calcium tungstate phosphor screen |
phosphor storage screen | Molecular Dynamics | BAS-IP MS 3543 E | |
Amersham Typhoon | GE Healthcare | ||
NAI (2M) | EMD Millipore | 03-310 | |
GlycoBlue | Thermo Fisher | AM9515 | |
SuperScript IV Reverse Transcriptase | Thermo Fisher | 18090010 | Contains 5X RT buffer, SuperScript IV |
dNTP mix (10 mM) | Thermo Fisher | R0192 | |
ddNTP set (5mM) | Sigma | GE27-2045-01 | |
large filter paper | Whatman | 1001-917 | |
Gel dryer | Hoefer | GD 2000 | |
QIAamp DNA Blood Mini Kit | Qiagen | 51104 | Also contains RNase A and protease K |
SMN2 minigene34 | Addgene | 72287 | |
Heat inactivated FBS | Thermo Fisher | 10438026 | |
Pen-Strep | Thermo Fisher | 15140122 | |
Opti-MEM I | Thermo Fisher | 31985062 | |
FuGene HD | Promega | E2311 | |
TrpLE | Thermo Fisher | 12605010 | |
DPBS without Ca/ Mg | Thermo Fisher | 14190250 | |
TRIzol | Thermo Fisher | 15596018 | |
RNeasy mini column | Qiagen | 74104 | Also contains RW1, RPE buffer |
RNase-Free DNase Set | Qiagen | 79254 | Contains DNase I and RDD buffer |
Deionized formamide | Thermo Fisher | AM9342 | |
MnCl2•4H2O | Sigma-Aldrich | M3634 | |
random nonamer | Sigma-Aldrich | R7647 | |
SuperScript First-Strand Synthesis System | Thermo Fisher | 11904-018 | Contains 10X RT buffer, SuperScript II reverse transcriptase |
AccuPrime pfx DNA polymerse | Thermo Fisher | 12344024 | |
NextSeq500 | Illumina | ||
NucAway column | Thermo Fisher | AM10070 | for desalting purpose |
Request permission to reuse the text or figures of this JoVE article
Request PermissionExplore More Articles
This article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved